Navigation Links
Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
Date:5/30/2013

New York, New York (PRWEB) May 30, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, and The Drakulich Firm, based in San Diego, have filed a lawsuit on behalf of an Arkansas man who developed pancreatic cancer and resulting injuries allegedly from using the diabetes drug Byetta. The suit was filed on May 28, 2013, in the U.S. District Court for the Southern District of California (Case No. 13-cv-99999). Amylin Pharmaceuticals LLC, Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have so far been named as Defendants.

According to the Complaint, the Plaintiff was prescribed and injected Byetta to treat his diabetes beginning around 2007 and continued using it at least until June 2012. On or about Feb. 25, 2013, a CT scan determined that the Plaintiff had pancreatic adenocarcinoma, the most common form of pancreatic cancer. Once diagnosed, the Plaintiff began treatment, which included chemotherapy and radiation therapy. He went on to develop jaundice.

The Complaint alleges that the Defendants knew or should have known that Byetta caused serious side effects, yet they continued to market and sell the drug by providing false and misleading information. The suit seeks damages for extensive pain and suffering, and severe emotional distress, among other things.

Byetta was approved by the U.S. Food Drug Administration (FDA) in 2005. It falls into a class of drugs called incretin mimetics, which work by mimicking the incretin hormones that the body usually naturally produces to stimulate the release of insulin after a meal. The drugs are used alo
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. How a cancer drug leads to diabetes
2. Heart failure patients with diabetes may benefit from higher glucose levels
3. Disrupted Sleep May Raise Risk for Obesity, Diabetes: Study
4. Mouse Study Hints at New Path for Diabetes Treatment
5. Common Plastics Chemical Might Boost Diabetes Risk
6. Weight-Loss Surgery Beat Drugs for Cutting Diabetes in Very Obese
7. Naturopathic care can improve blood sugar, mood in diabetes
8. Cellular pathway linked to diabetes, heart disease
9. Diabetes Groups Issue New Guidelines on Blood Sugar
10. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
11. Xenotransplantation as a therapy for type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The North America Phytochemicals & Plant Extracts Market ... in North America with analysis and forecast of revenue. This ... in 2012 to $930.1 million by 2018, at a CAGR ... TOC of the North America phytochemicals & plant extracts market ... It also provides a glimpse of the segmentation in the ...
(Date:7/31/2014)... The North American Colorants Market ... North America with analysis and forecast of volume ... North American Colorants Market report, to get an ... provides a glimpse of the segmentation in the ... various tables and figures. , http://www.micromarketmonitor.com/market/americas-colorants-8463333110.html ...
(Date:7/31/2014)... 2014 (HealthDay News) -- Many teens never outgrow their ... pain can persist for years, affecting teens, participation in ... left untreated, so-called growing pains can become chronic, the ... that one in three young people between the ages ... their knees," said Michael Skovdal Rathleff, a physiotherapist from ...
(Date:7/31/2014)... 2014 i2i Systems announced today it ... (SAS) to provide a robust patient referral database ... is one of the largest independent software companies in ... 40,000 patients are seen annually in its on-site HCC ... primary care, providers at the SAS HCC refer patients ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 With the brand ... a new lecture series featuring the “reality model” ... National Park, a more affordable resort pricing structure, and a ... Co-founder, says, “We have always had a great weight loss ... that differentiate Fitness Ridge. We want to change the way ...
Breaking Medicine News(10 mins):Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:Teen 'Growing Pains' May Persist For Years 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 3Health News:Weight Loss Destination, the Biggest Loser Resort in Utah, Rebrands as Fitness Ridge 2
... male veterans suffering from chronic obstructive pulmonary disease (COPD), ... cancer, researchers found that regular use of high dose ... cancer. ,David H. Au, M.D., M.S., of the ... along with five associates found that among 10,474 patients ...
... testosterone, which plays a key role in health and ... ,People suffering with Alzheimer's lack the ability to ... As the disease progresses, individuals may also experience changes ... agitation, as well as delusions or hallucinations. ...
... has over the years been a high source of nutrition ... that can be eaten in several forms, it is the ... With Easter just round the corner an animal rights group ... urging people not to eat eggs. ,Volunteers of ...
... fish varieties, is increasing all along the coastal regions in ... to it every year, it is estimated. // ... damage that pollution and global warming are inflicting on the ... of popular fish types, including grouper and barracuda, live near ...
... last year, has left Health Trusts short of nearly ?56million, ... from a local survey of health trusts show that almost ... money than they had expected to get under the new ... shortage, PCT may try to re allocate money from other ...
... overweight and obese individuals, the incidence of asthma increases ... weight, according to a meta-analysis of seven studies on ... first issue for April 2007 of the American Journal ... American Thoracic Society. ,E. Rand Sutherland, ...
Cached Medicine News:Health News:High Dose Inhaled Corticosteroid Use for COPD Could Cut Risk of Lung Cancer 2Health News:Global Warming Could Increase Exotic Fish Poisoning 2Health News:Asthma Incidence Shows a 50 Percent Increase in Fat People 2
(Date:7/31/2014)... WASHINGTON , July 31, 2014  CVS/pharmacy ... first pharmacy in the nation to earn the ... health care accreditation organization that establishes quality standards ... Longs Drug Store locations nationwide have earned this ... accreditation programs. Its Community Pharmacy Accreditation Program was ...
(Date:7/31/2014)... Mass., July 31, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced revenue of $70.1 million for the second quarter ... $50.8 million in revenue for the same period of ... ® Ventricular Assist Systems were sold globally compared ...
(Date:7/31/2014)... 2014 Second Quarter Total Revenue $2.0 billion; an increase of ... 4% for same store sales and 8% pro forma, excluding ... , 2014 Second Quarter GAAP EPS $0.37; Cash EPS $1.91, ... Operating Cash Flow $376 million; Adjusted Operating Cash Flow $500 ... Launched 17 new products in the U.S. year-to-date , ...
Breaking Medicine Technology:CVS/pharmacy Earns First-Ever Community Pharmacy Accreditation from URAC 2CVS/pharmacy Earns First-Ever Community Pharmacy Accreditation from URAC 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 2HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 5HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 6HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 7HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 8HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 9HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 10HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 11HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 3Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 4Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 5Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 6Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 7Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 8Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 9Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 10Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 11Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 13Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 14Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 15Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 16Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 17Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 18Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 19Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 20Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 21Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 22Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 23
... International Partnership for Microbicides, issued the following statement ... and effectiveness study of BufferGel and PRO2000 (0.5 ... Microbicide Trials Network, a worldwide collaborative group funded ... released final results from its Phase II/IIb safety ...
... Only Approved Platelet Producer in Europe Represents New ... Feb. 6 Amgen (Nasdaq: AMGN ... has granted marketing authorisation for Nplate(R) (romiplostim) for ... thrombocytopenic purpura (ITP) patients who are refractory to ...
Cached Medicine Technology:New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 2New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 3New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 2Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 3Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 5Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 6Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 7Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 8
... The Shandon Cytospin has been ... 35 years. More than 15,000 ... reliable instrument. It provides economical ... matrix, especially hypocellular fluids such ...
... Finger Traps for optimum patient comfort. The Nylon ... with a firm grip. ISI Nylon Finger Traps ... when used with the ISI Digi Grip or ... Traps are available in non-sterile packs and come ...
Spacelabs offers an approach that allows your telemetry and step-down units to configure systems to meet their telemetry requirements. Our modular telemetry system data are integrated into the depart...
The Tele-Pro WEP-4200 Telemetry System is an 8-Patient Stand Alone System. Offering capabilities such as arrhythmia analysis, trends and full disclosure, the Tele-Pro is a system to help hospitals to...
Medicine Products: